Literature DB >> 10727642

Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys.

J S Schneider1, J P Tinker, M Van Velson, M Giardiniere.   

Abstract

D-Cycloserine, a partial agonist at the glycine recognition site of the N-methyl-D-aspartate (NMDA) receptor complex, has been shown to facilitate certain forms of memory formation and to improve visual recognition memory in normal monkeys. In the present study, the effects of D-cycloserine on spatial short-term memory deficits in monkeys induced by chronic low-dose 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) administration were examined. Chronic low-dose MPTP administration resulted in deficits in the performance of a variable delayed-response task (VDR). Single administration of D-cycloserine (320 or 1000 microgram/kg) significantly improved the performance on this task. High-dose D-cycloserine (8000 microgram/kg) or MK-801 (10-32 microgram/kg) administration had no effects on delayed-response performance but impaired performance on a visual discrimination (VD) task that was not adversely affected by MPTP administration. These results show that at low doses, D-cycloserine has cognition-enhancing properties in this model of early Parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10727642     DOI: 10.1016/s0006-8993(00)02036-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  13 in total

Review 1.  Structural biological study of self-resistance determinants in antibiotic-producing actinomycetes.

Authors:  Masanori Sugiyama
Journal:  J Antibiot (Tokyo)       Date:  2015-04-15       Impact factor: 2.649

Review 2.  Cognitive enhancers for facilitating drug cue extinction: insights from animal models.

Authors:  Bríd Áine Nic Dhonnchadha; Kathleen M Kantak
Journal:  Pharmacol Biochem Behav       Date:  2011-02-02       Impact factor: 3.533

3.  Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease dementia in rats.

Authors:  Jin-Song Yang; Xiao-Hong Wu; Hao-Gang Yu; Li-Song Teng
Journal:  Inflammopharmacology       Date:  2017-06-02       Impact factor: 4.473

Review 4.  Cognition enhancement strategies.

Authors:  James A Bibb; Mark R Mayford; Joe Z Tsien; Cristina M Alberini
Journal:  J Neurosci       Date:  2010-11-10       Impact factor: 6.167

5.  D-cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window.

Authors:  Amos Adeleye; Esther Shohami; Dean Nachman; Alexander Alexandrovich; Victoria Trembovler; Rami Yaka; Yigal Shoshan; Jasbeer Dhawan; Anat Biegon
Journal:  Eur J Pharmacol       Date:  2009-12-01       Impact factor: 4.432

6.  Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.

Authors:  Donald C Goff; Corinne Cather; Jennifer D Gottlieb; A Eden Evins; Jared Walsh; Lisa Raeke; Michael W Otto; David Schoenfeld; Michael F Green
Journal:  Schizophr Res       Date:  2008-09-16       Impact factor: 4.939

7.  Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model.

Authors:  E Decamp; J S Schneider
Journal:  Brain Res       Date:  2009-02-07       Impact factor: 3.252

8.  Neuroinflammation-Induced Memory Deficits Are Amenable to Treatment with D-Cycloserine.

Authors:  Sigal Liraz-Zaltsman; Rami Yaka; Dalia Shabashov; Esther Shohami; Anat Biegon
Journal:  J Mol Neurosci       Date:  2016-07-16       Impact factor: 3.444

9.  D-cycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning.

Authors:  Bríd A Nic Dhonnchadha; Jonathan J Szalay; Cindy Achat-Mendes; Donna M Platt; Michael W Otto; Roger D Spealman; Kathleen M Kantak
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 10.  Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.

Authors:  Robert J Harvey; Benjamin K Yee
Journal:  Nat Rev Drug Discov       Date:  2013-11       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.